Olympus has launched its Olysense CAD/AI (artificial intelligence-powered computer-aided detection) portfolio in the U.S. and Europe.

The portfolio uses AI to allow earlier detection, boost outcomes, and improve care. In Europe, the launch includes clinical applications CADDIE, CADU, and SMARTIBD. It received CE mark certification under the EU MDR with CADDIE covering both computer-aided detection (CADe) and diagnosis (CADx) of suspected colorectal polyps.

In the U.S., the launch includes CADDIE with detection capabilities only. The computer-aided detection device won 510(k) clearance to help gastroenterologists detect suspected polyps during colonoscopies. CADDIE is available in the U.S. with only polyp detection and excludes polyp characterization features.

Olysense CAD/AI is a suite of cloud-based, AI-powered apps and marks the company’s first step in its intelligent endoscopy system. The apps support clinicians in detecting, characterizing, and analyzing lesions in the upper and lower GI tract.

CADDIE, trained on a robust dataset, analyzes colonoscopy video frames to help identify lesions, including large polyps and hard-to-detect ones like sessile serrated lesions (SSLs). CADU supports detection of dysplasia in endoscopy images to support more accurate clinical decisions.

SMARTIBD supports objective assessment of ulcerative colitis through MAYO scoring system. It can analyze the visual characteristic and offer info to help users and decrease subjectivity in the decision-making process.

With Olysense, Olympus hopes to integrate clinical and operational solutions to provide data connectivity across the GI unit and integration with hospital systems. The company said it plans to expand Olysense in the long-term.

“With OLYSENSE, we are taking a meaningful step forward in helping patients receive earlier, more accurate diagnoses,” said Keith Boettiger, corporate officer, head of Gastrointestinal Solutions division, Olympus. “Our goal is simple: to give clinicians the advanced tools that make it easier to find and assess challenging lesions early, make confident, informed decisions, and provide their patients with the best possible care.”